Home > Insider Trading > Filing (0001209191-17-060971)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1423824	Alder Biopharmaceuticals Inc	ALDR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1604834	James Mark Litton	11804 North Creek Parkway South Bothell WA 98011	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-13	16,519	$1.65	116,451	No	4	M	Direct
Common Stock	Disposition	2017-11-13	16,519	$10.80	99,932	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-11-13	16,519	$0.00	16,519	$1.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2018-07-22	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	26,000	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	26,000	Indirect	Held in trust for the benefit of Reporting Person's minor child
Common Stock	26,000	Indirect	Held in trust for the benefit of Reporting Person's minor child

Footnotes

The exercise of options reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2016.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.55 to $11.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
The option is fully vested.